临床特应性皮炎严重程度指标中更高的应答水平与患者报告症状和生活质量指标的具有临床意义的改善相关:三项Upadacitinib 3期试验的整合分析
该事后分析纳入三项随机双盲安慰剂对照3期试验(Measure Up 1、Measure Up 2和AD Up)中2392例中重度特应性皮炎成人和青少年患者,按EASI和vIGA-AD应答水平分层,评估第16周时患者报告结局(瘙痒、症状、睡眠、焦虑、抑郁、生活质量、工作效率)的改善程度。结果显示,临床应答水平越高,患者报告结局的平均改善百分比和应答比例越大,呈阶梯式模式。
要点
- 临床应答水平越高,患者报告结局改善越显著,呈阶梯式模式。
- EASI ≥90和vIGA-AD 0/1应答者中,大多数PRO的平均改善百分比和应答比例分别超过69%和70%。
- 临床应答与瘙痒、皮肤疼痛、睡眠、焦虑、抑郁及生活质量等多维度改善相关。
核心结论
- 更高程度的临床应答与特应性皮炎影响的多维度(包括瘙痒、皮肤疼痛、睡眠、焦虑、抑郁和生活质量)更稳健的改善相关。
研究设计与样本
- 三项随机、双盲、安慰剂对照3期试验(Measure Up 1、Measure Up 2和AD Up)的事后分析,纳入2392例中重度特应性皮炎成人和青少年患者。
- 患者按1:1:1随机分配至Upadacitinib 15 mg、30 mg或安慰剂每日一次(单用或联合外用糖皮质激素)。
主要发现
- 在更高临床应答水平(即EASI和vIGA-AD应答类别)下,观察到平均改善百分比和达到应答的患者比例逐步增加(阶梯式模式)。
- 在EASI ≥90和vIGA-AD 0/1应答者中,大多数PRO(包括最严重瘙痒数字评定量表、患者导向湿疹测量和皮肤病生活质量指数)的平均改善百分比和达到应答的患者比例分别超过69%和70%。
关键数值与推荐
- EASI ≥90和vIGA-AD 0/1应答者中,大多数PRO的平均改善百分比超过69%,达到应答的患者比例超过70%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is not fully understood how different degrees of improvements in atopic dermatitis (AD) clinical outcome measures translate to improvements in patient-reported outcome (PRO) measures, such as those assessing itch, symptoms, sleep, anxiety, depression, quality of life (QoL), and work productivity. OBJECTIVES: This post hoc analysis of three clinical studies assessed how more robust improvements in clinical responses are associated with improvements in PROs and QoL. METHODS: Data from three randomized, double-blind, placebo-controlled, phase 3 trials in adults and adolescents with moderate to severe atopic dermatitis (Measure Up 1, Measure Up 2, and AD Up) were included. Patients were randomly assigned (1:1:1) to upadacitinib (15 or 30 mg) or placebo once daily (alone or in combination with topical corticosteroids). The mean percentage improvement from baseline to week 16 and percentage of patients achieving responses at week 16 were summarized by the Eczema Area and Severity Index (EASI) and validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) response level categories. RESULTS: A total of 2392 patients from the three trials were included in the analysis. Increasingly greater mean percentage improvement and proportion of patients achieving response was observed at higher clinical response levels (i.e., stepwise pattern). Mean percentage improvement and proportion of patients achieving response exceeded 69% and 70% at EASI ≥ 90 and vIGA-AD 0/1, respectively, for most PROs including Worst Pruritus Numeric Rating Scale, Patient Oriented Eczema Measure, and Dermatology Life Quality Index. CONCLUSIONS: Greater degrees of clinical responses are related to more robust improvements across multiple dimensions impacted by AD, including itch, skin pain, sleep, anxiety, depression, and QoL.
引用
- Reich K, de Bruin-Weller MS, Deleuran M, et al. Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials. J Eur Acad Dermatol Venereol. 2023. PMID: 36840396. doi:10.1111/jdv.18995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。